Tariq Musa 4

What Happened
Tariq Musa, a director of Guardant Health (GH), sold 116 shares in an open-market transaction on 2026-06-16 at $130.19 per share, totaling $15,102. The filing also shows a conversion/exercise of 250 derivative units into 250 shares on 2026-06-15 (no cash exercise price, code M) and a related disposition of 250 shares on 2026-06-15 recorded as a derivative disposal (code M, $0). The primary public action here is the 116-share sale (often routine liquidity), while the June 15 entries reflect vesting/conversion activity of previously granted awards.

Key Details

• Transactions:
  • 2026-06-15: Conversion/exercise of derivative (code M) — 250 shares acquired at $0.00 (likely RSUs vesting; see footnote).
  • 2026-06-15: Derivative disposition (code M) — 250 shares disposed at $0.00.
  • 2026-06-16: Open-market sale (code S) — 116 shares at $130.19, gross proceeds $15,102.
• Filing: Form 4 filed 2026-06-16 (timely relative to the reported transaction dates).
• Shares owned after transaction: Not specified in this filing.
• Footnotes: F1 notes the underlying award is a restricted stock unit (RSU) grant from March 6, 2023 that vests over four years (25% on 3/15/2024, remainder monthly over three years). F2: Not applicable for RSUs.

Context

• The June 15 conversion (code M) reflects RSUs converting into common shares (no cash exercise price). The back-to-back disposal and subsequent open-market sale are consistent with common post-vesting actions (e.g., sell-to-cover tax obligations or partial liquidation), but the filing itself does not state the specific reason.
• Sales by directors are routine and do not, by themselves, prove a change in personal view of the company. Purchases are typically considered more informative about insider optimism.